```json
{
"content": [
{
"type": "paragraph",
"content": "North America dominates the Neurotrophic Keratitis Treatment market, accounting for ~35% of global revenue in 2023. High adoption of advanced therapies, robust R&D investments, and favorable reimbursement policies drive this leadership. The regionโs mature healthcare ecosystem and aging demographics further fuel demand for innovative treatments like recombinant human nerve growth factor (rhNGF)."
},
{
"type": "paragraph",
"content": "Asia Pacific is the fastest-growing region, with a projected CAGR exceeding 12% from 2024โ2030. Rising awareness of rare diseases, expanding insurance coverage, and government partnerships with biotech firms are key enablers. Countries like India and China are prioritizing infrastructure upgrades, enhancing access to specialized ophthalmic care."
},
{
"type": "paragraph",
"content": Europe holds ~25% market share, driven by stringent regulatory frameworks ensuring treatment safety, coupled with cross-border collaborations for clinical trials. Germany and France lead in adoption due to high healthcare spending and a strong presence of key pharmaceutical players."
},
{
"type": "paragraph",
"content": Latin America (~15% share) and the Middle East & Africa (~5% share) face infrastructure gaps but show potential due to emerging public-private partnerships. Latin America benefits from increased medical tourism, while the Middle East invests heavily in healthcare modernization to address unmet needs."
}
],
"worldMapData": {
"regions": [
{ "name": "North America", "value": 35 },
{ "name": "Europe", "value": 25 },
{ "name": "Asia Pacific", "value": 20 },
{ "name": "Latin America", "value": 15 },
{ "name": "Middle East & Africa", "value": 5 }
]
}
}
```
